Positive News SentimentPositive NewsNASDAQ:IVVD Invivyd (IVVD) Stock Price, News & Analysis $1.20 -0.02 (-1.64%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Invivyd alerts: Email Address About Invivyd Stock (NASDAQ:IVVD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Invivyd alerts:Sign Up Key Stats Today's Range$1.18▼$1.2450-Day Range$0.81▼$1.3952-Week Range$0.81▼$5.20Volume1.24 million shsAverage Volume677,316 shsMarket Capitalization$143.18 millionP/E RatioN/ADividend YieldN/APrice Target$11.33Consensus RatingBuy Company OverviewInvivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Read More… “Buffett Indicator” Predicts 62% Stock Market Crash (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Invivyd Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 66th PercentileInvivyd scored higher than 66% of companies evaluated by MarketBeat, and ranked 407th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInvivyd has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInvivyd has only been the subject of 1 research reports in the past 90 days.Read more about Invivyd's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($0.60) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Invivyd's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.52% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.Change versus previous monthShort interest in Invivyd has recently decreased by 3.17%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.52% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.Change versus previous monthShort interest in Invivyd has recently decreased by 3.17%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News SentimentN/A News SentimentInvivyd has a news sentiment score of 1.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Invivyd this week, compared to 2 articles on an average week.Search Interest4 people have searched for IVVD on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows4 people have added Invivyd to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have not sold or bought any company stock.Percentage Held by Insiders17.90% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invivyd's insider trading history. Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Email Address IVVD Stock News HeadlinesInvivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19September 12, 2024 | globenewswire.comBuy Rating Affirmed for Invivyd: Strong Product Performance and Strategic Market InitiativesSeptember 9, 2024 | markets.businessinsider.comOur #1 Ticker for the Rare "Retirement Window"We've only seen this happen three times in the past 20 years... And every time - like clockwork - it's minted an entire new class of millionaires.September 20, 2024 | Behind the Markets (Ad)Invivyd to Participate in Upcoming Investor ConferencesSeptember 5, 2024 | globenewswire.comInvivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™September 4, 2024 | globenewswire.comBuy Rating Affirmed for Invivyd Amid Strong Potential of PEMGARDA Antibody for COVID-19 VariantsSeptember 3, 2024 | markets.businessinsider.comInvivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of InterestSeptember 3, 2024 | globenewswire.comBuy Rating on Invivyd Backed by Strong Phase 3 Data and Market CatalystsAugust 29, 2024 | markets.businessinsider.comSee More Headlines IVVD Stock Analysis - Frequently Asked Questions How have IVVD shares performed this year? Invivyd's stock was trading at $3.94 on January 1st, 2024. Since then, IVVD stock has decreased by 69.5% and is now trading at $1.20. View the best growth stocks for 2024 here. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.03. The business earned $2.26 million during the quarter, compared to analyst estimates of $4.91 million. Who are Invivyd's major shareholders? Top institutional investors of Invivyd include Marshall Wace LLP (0.66%), Acadian Asset Management LLC (0.57%), Duquesne Family Office LLC (0.48%) and Renaissance Technologies LLC (0.32%). View institutional ownership trends. How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/14/2024Today9/20/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IVVD CUSIPN/A CIK1832038 Webadagiotx.com Phone781-819-0080FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+852.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-198,640,000.00 Net MarginsN/A Pretax Margin-9,003.40% Return on Equity-109.72% Return on Assets-90.91% Debt Debt-to-Equity RatioN/A Current Ratio4.71 Quick Ratio4.57 Sales & Book Value Annual Sales$2.26 million Price / Sales62.71 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book0.74Miscellaneous Outstanding Shares119,316,000Free Float97,958,000Market Cap$141.99 million OptionableOptionable Beta0.61 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:IVVD) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.